Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) traded down 2.4% during mid-day trading on Monday . The stock traded as low as $3.15 and last traded at $3.21, with a volume of 194,084 shares trading hands. The stock had previously closed at $3.29.

Several analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 9th. HC Wainwright assumed coverage on shares of Anthera Pharmaceuticals in a research report on Friday, July 8th. They issued a “buy” rating and a $10.00 price target for the company. Finally, FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Anthera Pharmaceuticals presently has an average rating of “Buy” and an average target price of $9.58.

The company’s market cap is $126.24 million. The firm’s 50-day moving average is $3.35 and its 200 day moving average is $3.46.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. On average, equities analysts anticipate that Anthera Pharmaceuticals Inc. will post ($1.26) earnings per share for the current year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.